Longboard Pharmaceuticals, Inc., (LBPH): Price and Financial Metrics

Longboard Pharmaceuticals, Inc., (LBPH): $5.03

0.29 (+6.12%)

POWR Rating

Component Grades













Add LBPH to Watchlist
Sign Up

Industry: Biotech



in industry

LBPH Stock Price Chart Interactive Chart >

Price chart for LBPH

LBPH Price/Volume Stats

Current price $5.03 52-week high $18.50
Prev. close $4.74 52-week low $3.90
Day low $4.58 Volume 10,100
Day high $5.15 Avg. volume 20,821
50-day MA $5.01 Dividend yield N/A
200-day MA $6.30 Market Cap 68.34M

Longboard Pharmaceuticals, Inc., (LBPH) Company Bio

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.

LBPH Latest News Stream

Event/Time News Detail
Loading, please wait...

LBPH Latest Social Stream

Loading social stream, please wait...

View Full LBPH Social Stream

Latest LBPH News From Around the Web

Below are the latest news stories about Longboard Pharmaceuticals Inc that investors may wish to consider to help them evaluate LBPH as an investment opportunity.

Longboard Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present at the H.C. Wainwright BioConnect Virtual Conference. The presentation webcast will be available beginning Monday, January 10, 2022, at 7:00 AM ET. To access a webcast of the presentation, please visit the “Even

Yahoo | January 5, 2022

Longboard Pharmaceuticals (NASDAQ:LBPH) Cut to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Longboard Pharmaceuticals (NASDAQ:LBPH) from a buy rating to a hold rating in a research report report published on Tuesday, Zacks.com reports. According to Zacks, Longboard Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel, transformative medicines for neurological diseases. Longboard Pharmaceuticals Inc. is based in SAN []

Transcript Daily | December 22, 2021

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | December 9, 2021

Longboard Pharmaceuticals (NASDAQ:LBPH) Lifted to Buy at Zacks Investment Research

Longboard Pharmaceuticals (NASDAQ:LBPH) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Tuesday, Zacks.com reports. The firm presently has a $6.50 target price on the stock. Zacks Investment Researchs price objective points to a potential upside of 23.81% from the companys previous close. [] The post Longboard Pharmaceuticals (NASDAQ:LBPH) Lifted to Buy at Zacks Investment Research appeared first on ETF Daily News .

ETF Daily News | December 7, 2021

Longboard Pharmaceuticals, Inc. (LBPH) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Longboard Pharmaceuticals, Inc. (LBPH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Yahoo | December 6, 2021

Read More 'LBPH' Stories Here

LBPH Price Returns

1-mo 3.07%
3-mo 5.45%
6-mo -14.75%
1-year -40.54%
3-year N/A
5-year N/A
YTD 3.07%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8005 seconds.